RHOA Therapeutic Targeting in Hematological Cancers

Area of Science:

• Molecular Biology
• Cell Biology
• Oncology

Background:

• Ras homolog gene family member A (RHOA), a small GTPase, is a key regulator of cytoskeletal dynamics.
• RHOA influences critical cellular processes including survival, migration, adhesion, and proliferation.
• Aberrant RHOA activity is associated with the development and metastasis of various cancers.

Purpose of the Study:

• To review the molecular mechanisms of RHOA GTPase in immune regulation.
• To explore RHOA's role in the pathogenesis of hematological neoplasms.
• To discuss current therapeutic strategies targeting RHOA in these diseases.

Main Methods:

• Review of existing literature on RHOA function in cellular processes.
• Analysis of recent cancer genome-wide sequencing data related to RHOA mutations in leukemia/lymphoma.
• Synthesis of information on RHOA signaling pathways and therapeutic interventions.

Main Results:

• RHOA mutations (both gain and loss-of-function) are found in primary leukemia/lymphoma.
• RHOA can exhibit context-dependent tumor-promoting or tumor-suppressive functions in hematological malignancies.
• RHOA signaling is a promising target for developing selective anticancer therapies.

Conclusions:

• RHOA plays a significant, context-dependent role in hematological neoplasms.
• Targeting RHOA signaling offers a potential therapeutic avenue for leukemia and lymphoma.
• Further research into RHOA modulation is warranted for effective cancer treatment.